Cytodyn Inc (CYDY)

[HyGro]

Need to remind everybody, the remdesivir is NOT lenacapavir. Gilead owns HIV and has been spending decades and billions in R&D developing the marketing leading portfolio of HIV medical technologies.

This is a novel mode of action that covers all types of HIV and all stages from PrEP to heavily treated HAART-resistant.

81-95% efficacy depending on HAART drugs it is used with(LL 81% for mixed combinations), TWICE a year dosing (LL 52x), safety=placebo. Oral option.
Approval expected 2/28/22 (LL who knows?).

It is not going to be pretty if LL comes to market a year after Gilead has had time to launch and take over HIV combo market.

You can build any story you want, but NP's incompetence and self-serving insider trading have put the company two years behind Gilead. Not going to be pretty.